\square

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burde	en									
hours per response:	0.5									

1. Name and Address of Reporting Person [*] KINGSLEY ALFRED D			2. Issuer Name and Ticker or Trading Symbol BIOTIME INC [BTX]		tionship of Reporting all applicable) Director	Persor X	n(s) to Issuer 10% Owner
(Last) 150 E. 57TH STH	t) (First) (Middle) E. 57TH STREET		3. Date of Earliest Transaction (Month/Day/Year) 11/15/2012	Х	Officer (give title below) See Remarks		Other (specify below)
(Street) NEW YORK (City)	NY (State)	10022 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	idual or Joint/Group F Form filed by One F Form filed by More Person	Reporti	ing Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

					• • •							
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)					5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)		
Common Shares, no par value	11/15/2012		S ⁽¹⁾		344,828	D	\$2.9	7,167,566 ⁽²⁾	D			
Common Shares, no par value								1,968,505	I	By Greenbelt Corp.		
Common Shares, no par value								490,373	I	By Greenway Partners, LP		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

(
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of E		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Option to Puchase Common Shares	\$4.6							(3)	06/30/2017	Common Shares	50,000		50,000	D	
Option to Puchase Common Shares	\$5.13							(4)	06/30/2016	Common Shares	50,000		50,000	D	
Option to Puchase Common Shares	\$5.45							(5)	08/09/2015	Common Shares	50,000		50,000	D	
Option to Puchase Common Shares	\$2.3							(6)	07/01/2014	Common Shares	50,000		50,000	D	

Explanation of Responses:

1. On November 15, 2012, Mr. Kingsley sold 344,828 BioTime common shares in a private transaction.

2. Does not include shares that Mr. Kingsley may acquire through the exercise of certain options.

3. 12,500 options became exercisable on September 30, 2012 and the remaining 37,500 options will become exercisable in 3 equal quarterly installments based upon continued service on the board of directors.

4. 12,500 options became exercisable on September 30, 2011; December 31, 2011; March 31, 2012; and June 30, 2012.

5. 12,500 options became exercisable on September 30, 2010; December 31, 2010; March 31, 2011; and June 30, 2011.

6. 12,500 options became exercisable on September 30, 2009; December 31, 2009; March 31, 2010; and June 30, 2010.

Remarks:

Mr. Kingsley is Executive Chairman of certain BioTime subsidiaries.

/s/ Alfred D. Kingsley

11/19/2012

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.